

Releasing product potential with rapid dissolve tablets



Introducing InstaPill™

InstaPill™ uses proprietary drug delivery technology to help you produce fast-dissolving, convenient medication for your patients and consumers.

Our rapid dissolve tablet (RDT) technology is ideal for supporting lifecycle management projects, overcoming formulation challenges - specifically for products with low bioavailability - and meeting patient preferences for over-the-counter (OTC) medications when it comes to orally disintegrating tablets (ODT).

We use the deep expertise of InstaPill™ and our parent company Tenshi Kaizen to navigate complex formulation projects, offering flexible and agile solutions that meet your requirements and get your products to market quickly.

By catering for product design and development across clinical programs and commercial manufacture, we improve efficiency and reduce cost and complexity.

Driven to achieve the best outcomes for customers we unlock the true potential of your product to make sure you never miss an opportunity. It's what we do all day, every day.

InstaPill™. Releasing product potential.



The InstaPill™ edge

INCREASING BIOAVAILABILITY

- Dissolves in less than 10 seconds, ideal for medications where fast dispersion is desirable, for example, anaphylaxis treatment, motion sickness, migraines and pain relief.
- Pre-gastric absorption through the local oromucosal, sublingual or buccal tissues making our RDTs ideal for medications where bioavailability of the active ingredient is low.
- Ability to tailor formulations to enable faster onset of therapeutic action.

IMPROVING PATIENT CONVENIENCE AND COMPLIANCE

- No need to swallow, ideal for improving RX compliance in patients suffering from dysphagia i.e. geriatric and pediatric patient populations.
- On-the-go administration for improved patient convenience giving your OTC product a competitive edge.
- Taste masking and flavor enhancement formulations developed and validated in an independent GLP and GMP-compliant lab.

EXTENDING YOUR PRODUCT LIFECYCLE

- Lifecycle management programs extending patent lifecycles and improving formulations using novel delivery formats.
- Customized solutions can offer potential exclusivities using regulatory strategies such as 505(b)(2) and access to large-scale lyophilization ODT technologies.
- Alternative administration method for injectable medications, such as vaccines, as well as combination products and therapeutics for neurological disorders including Alzheimer's and Parkinson's.

MAKING MEDICATION MORE ACCESSIBLE

- Gelatin-free to meet market demand for products free from animal-derivatives.

Manufacturing capabilities

From our state-of-the-art manufacturing facility in India, InstaPill™ offers highly automated operations to improve speed, accuracy and quality, as well as ensuring dosage uniformity and precision.

BENGALURU

- USFDA, TGA, HC and EU GMP approved site.
- Capacity to manufacture 70 million RDTs annually.
- Dedicated lyophilized ODT R&D center.
- Specialist aseptic and lyophilization capabilities for molecules with more challenging handling requirements.
- Advanced taste-masking and flavor-enhancing techniques.
- Expertise in clinical affairs, regulatory and analytical capabilities.
- Lab scale studies and scale-up including clinical batch manufacturing.

FUTURE EXPANSION

- 21 CFR Part 11 compliant line with global serialization requirements incorporated, adaptable to e-batch record manufacturing.
- Increased capacity to produce 200 million RDTs annually.
- Integrated end to end line - from base foil introduction to case package collection.
- Extensive automation to provide high cGMP compliance.
- Auto Guided Vehicle (AGV) system introduced for loading and unloading of blister tray to/from Lyophilizer.

Stand out from the crowd

We are a partner of choice for the development of RDTs that facilitate brand lifecycle management solutions. Our platform can be easily extended to a wide range of products across multiple therapeutic classes and dosage strengths.

In addition to InstaPill™ infusing new life into your brand, we offer solutions to help develop products with enhanced marketing claims, novel delivery formats, superior caregiver and patient experience and potential exclusivities in the market through regulatory strategies including 505(b)(2).

Several products from the InstaPill™ platform have already been approved in the regulated markets of the US, Canada and Australia.

Infuse new life into your brand

Visit our website: www.insta-pill.com

Call us on: +918067840222

Or email: hello@insta-pill.com

ABOUT TENSHI KAIZEN (TK)

The InstaPill™ platform is a proprietary technology owned by Tenshi Kaizen (TK). TK is focused on delivering advanced finished dosage products driven by proprietary technology platforms, global infrastructure, and a robust quality system. Our strategy is aligned with the founder's ethos of producing reliable and cost-effective pharmaceuticals with speed and agility.

As of today, Tenshi Kaizen has investments in two proprietary technology platforms:

- InstaPill™ - technology for rapid dissolve tabs
- Med StrainBoost™ - the world's first thermostable probiotics platform

Building on our strong global network, we are committed to fulfilling the demands of the world markets by anticipating the future needs and pioneering strategic new in-roads into the commercial pharmaceutical sector.

Where rapid dissolve
expertise meets imagination

